MustangBio
    • About
      • About Mustang Bio
      • Leadership
      • Board of Directors
      • In the News
      • Contact
    • Our Approach
      • Our Approach
      • About Gene Therapy
      • About CAR T Cell Therapy
      • Publications
      • Manufacturing
    • Pipeline
      • Pipeline
      • Clinical Trials
    • Partnering
      • Partnering
      • Active Collaborations
    • Careers
    • Investor Relations
      • News & Events
      • Company Info
      • Financial Info
      • Stock Data
      • SEC Filings
      • Governance

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    March 9, 2022

    Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

    March 8, 2022

    Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital

    February 15, 2022

    Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

    February 8, 2022

    Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards

    January 24, 2022

    Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

    January 7, 2022

    Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

    January 5, 2022

    Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

    December 16, 2021

    Mustang Bio Added to the NASDAQ Biotechnology Index

    December 13, 2021

    Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    December 9, 2021

    Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

    • arrow_back
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • …
    • 15
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    377 Plantation Street • Worcester, MA 01605

    781-652-4500 info@mustangbio.com

    Twitter Linkedin

    © Copyright 2023 Mustang Bio